EUCTR2007-003565-40-SE进行中（未招募）1 期
An open-label randomized Phase II study of PA21 compared to sevelamer to evaluate the ability of PA21 to control serum phosphate levels and the tolerability in patients with chronic kidney disease undergoing hemodialysis
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 220
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Inclusion Criteria at Screening
- •Patients will be entered into this study only if they meet all of the following criteria, at screening:
- •1. =18 years of age,
- •2. Receiving maintenance hemodialysis 3 times a week for =3 months,
- •3. Receiving stable doses of phosphate binder for at least 1 month before screening (with or without vitamin D or vitamin D metabolite therapy). Patients receiving vitamin D therapy must remain on the same dose throughout the study,
- •4. Having stable calcium content in dialysate,
- •5. Able to read and write with sufficient competence to understand the study procedures and capable of giving legal consent,
- •6. Able to provide written informed consent.
- •Inclusion Criteria for Entry into the Treatment Period
- •To be eligible for randomization and to enter into the treatment period, the patients must meet the following serum phosphate level condition either after 1 week of washout or at the end of the allowed 2-week washout period:
- •7. Having serum phosphate levels >1.76 mmol/L (5.5 mg/dL) and =3.0 mmol/L (9.3 mg/dL) after a washout period for previous phosphate binders (up to 2 weeks).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Uncontrolled hyperphosphatemia (>2.5 mmol/L) while on conventional phosphate binders (value at screening),
- •2. Serum phosphate >3.0 mmol/L after the start of washout,
- •3. Hypercalcemia (serum calcium >2.5 mmol/L) at screening or during washout,
- •4. Serum calcium < 1.9 mmol/L at screening or during washout,
- •5. Severe hyperparathyroidism (iPTH levels >800 ng/L),
- •6. History of parathyroidectomy,
- •7. Intention to initiate therapy with vitamin D, vitamin D metabolites or calcimimetics during the study,
- •8. Non-stable therapy with vitamin D, vitamin D metabolites or calcimimetics (if applicable),
- •9. Known to be non-responder to phosphate binders,
- •10. Known hypersensitivity to PA21, sevelamer (as Renagel®), or to any of their excipients, or iron allergy,
- •11. Pregnancy or lactation,
- •12. Lack of highly effective contraception in female patients of child-bearing potential:
- •This excludes any female patient who is not currently using or is not willing to continue to use a highly effective method of birth control ie, implants, injectables, combined oral contraceptives, intrauterine device, sexual abstinence, unless she is surgically sterilized (tubal ligation and/or hysterectomy), post-menopausal (amenorrhea for at least 1 year before screening) or has a vasectomized partner
- •13. Significant gastrointestinal disorder (including known active peptic ulcer, Crohn’s disease, ulcerative colitis, irritable bowel syndrome, motility disorder of the intestines [symptomatic gastroparesis {treated or untreated}, ileus, pseudo-obstruction, megacolon, or mechanical obstruction] and history of major gastrointestinal surgery),
- •14. Hepatitis B (hepatitis B surface antigen [HBsAg] positivity only), hepatitis C (hepatitis C virus ribonucleic acid [HCV RNA] positivity only) or other significant concurrent liver disorders (alanine transaminase [ALT] or aspartate transaminase [AST] >3 times the upper limit of the normal range),
- •15. Intention to change diet during the study,
- •16. Known or suspected non-compliance with dietary phosphate restrictions,
- •17. Known infection with human immunodeficiency virus (HIV),
- •18. History of drug or alcohol abuse within 2 years before screening,
- •19. Use of antacids containing aluminum or magnesium within 1 month before screening,
- •20. Serious medical condition, uncontrolled systemic disease (eg, poorly controlled diabetes mellitus, hypertension, active malignant disease within the last 5 years [except non-melanotic skin cancer] planned surgery including kidney transplantation during study, or suspected life-expectancy of <12 months per Investigator’s assessment),
- •21. Inability to fully comprehend and/or perform study procedures (in the Investigator’s opinion),
- •22. Receipt of any other investigational drug <30 days before the study or during the study.
研究者
相似试验
进行中（未招募）
不适用
An open-label randomized Phase II study of PA21 compared to sevelamer to evaluate the ability of PA21 to control serum phosphate levels and the tolerability in patients with chronic kidney disease undergoing hemodialysisEUCTR2007-003565-40-GBVifor (International) Inc.220
进行中（未招募）
不适用
An open-label randomized Phase II study of PA21 compared to sevelamer to evaluate the ability of PA21 to control serum phosphate levels and the tolerability in patients with chronic kidney disease undergoing hemodialysispatients with chronic kidney disease undergoing hemodialysishyperphosphatemiaMedDRA version: 9.1Level: LLTClassification code 10020712Term: HyperphosphatemiaEUCTR2007-003565-40-DEVifor (International) Inc.220
进行中（未招募）
1 期
FOLFOXIRI with or without panitumumab in metastatic colorectal cancerEUCTR2009-017731-17-DEAIO-Studien-gGmbh93
进行中（未招募）
1 期
An open label, multicenter, Phase I/II study of pazopanib in combination with paclitaxel in first line treatment of subjects with stage IIIBwet/IV non-small cell lung cancerPart I: Subjects with histologically or cytologically confirmed diagnosis of advanced solid tumours for which there is no standard therapy or for whom paclitaxel is standard therapy. Part II: Stage IIIB wet (with histologically- or cytologically-confirmed malignant pleural effusion) or Stage IV NSCLCMedDRA version: 9.1 Level: LLT Classification code 10029521 Term: Non-small cell lung cancer stage IIIBMedDRA version: 9.1 Level: LLT Classification code 10029522 Term: Non-small cell lung cancer stage IVEUCTR2009-010571-24-GBGlaxoSmithKline Research & Development Limited
进行中（未招募）
1 期
A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients with Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of DosesChronic Phase Chronic Myeloid LeukemiaMedDRA version: 19.0Level: LLTClassification code 10054352Term: Chronic phase chronic myeloid leukemiaSystem Organ Class: 100000004864EUCTR2014-001617-12-NLARIAD Pharmaceuticals, Inc.450